GleamWall
中文EN

PROF Profound Medical Corp.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1628808 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY65.3%
TTM net income YoY17.4%
TTM EPS YoY295.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin73.9%
Operating margin-145.1%
Net margin-137.5%
FCF margin—
EBITDA margin-143.4%

Returns

ROE-87.0%
ROA-64.7%
ROIC (approx.)-157.1%
Asset turnover0.47x

Leverage & solvency

Liabilities / assets26.9%
Debt / equity0.21x
Current ratio4.54x
Interest coverage-105.79x

Cash quality & payout

Operating cash flow / net income0.97x
Accruals ratio-2.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY2022*2022-12-31FY2021*2021-12-31
Income statement
Revenue$16.10M$10.68M$7.20M$6.68M$6.87M
Cost of revenue$4.71M$3.64M$2.89M$3.66M$3.92M
Gross profit$11.39M$7.04M$4.31M$3.02M$2.95M
R&D expense$20.60M$16.96M$14.42M$14.69M$15.28M
SG&A expense$32.05M$23.13M$18.54M$9.46M$10.31M
Operating income-$41.25M-$33.06M-$28.65M-$32.13M-$30.29M
Interest expense$394,000$600,000$146,000$290,000$448,000
Pretax income-$42.32M-$27.82M-$28.45M-$28.38M-$30.59M
Income tax$252,000-$2,000-$128,000$287,000$105,000
Net income-$42.57M-$27.82M-$28.32M-$28.67M-$30.70M
EBITDA-$40.88M-$32.35M-$27.92M-$30.52M-$28.41M
EPS (basic)1.411.121.341.381.50
EPS (diluted)1.411.121.341.381.50
Weighted avg. shares (diluted)30.23M24.77M21.18M——
Banking
Net interest income——$1.64M$803,000$205,000
Balance sheet
Cash & equivalents$59.72M$54.91M$26.21M$46.52M$67.15M
Receivables——$7.29M$6.34M$1.41M
Inventory$8.24M$5.80M$6.99M$7.94M$7.41M
Current assets$76.09M$69.06M$41.90M$62.02M$77.12M
PP&E, net$698,000$425,000$909,000$899,000$788,000
Goodwill————$2.69M
Intangibles$138,000$261,000$490,000$680,000$1.44M
Total assets$77.47M$70.23M$43.96M$64.42M$86.78M
Current liabilities$6.08M$6.57M$6.37M$4.18M$4.16M
Short-term debt—$1.74M$2.10M$523,000—
Long-term debt$4.50M$4.66M$7.10M$7.17M—
Total debt$4.50M$6.40M$9.21M$7.70M—
Total liabilities$11.04M$9.81M$12.73M$12.42M$6.16M
Shareholders' equity$66.43M$60.42M$31.22M$52.60M$80.62M
Net debt-$55.22M-$48.51M-$17.00M-$38.82M—
Shares outstanding36.29M30.04M21.37M——
Cash flow statement
Operating cash flow-$38.21M-$23.45M-$22.61M-$25.80M-$22.36M
Capital expenditure$176,000———$32,000
Free cash flow-$38.38M———-$22.39M
Investing cash flow-$242,000———-$593,000
Financing cash flow$41.14M$54.70M$1.76M$7.03M$5.95M
Depreciation & amortization$373,000$707,000$727,000$1.60M$1.88M
Stock-based compensation$5.49M$2.58M$3.42M$4.24M$7.21M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.